Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Standard Biotools (LAB) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Standard Biotools (LAB) over the last 16 years, with Q3 2025 value amounting to -$2.1 million.

  • Standard Biotools' Non Operating Income fell 31859.98% to -$2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year increase of 94102.56%. This contributed to the annual value of -$5.2 million for FY2024, which is 47181.88% down from last year.
  • As of Q3 2025, Standard Biotools' Non Operating Income stood at -$2.1 million, which was down 31859.98% from $5.0 million recorded in Q2 2025.
  • In the past 5 years, Standard Biotools' Non Operating Income ranged from a high of $5.0 million in Q2 2025 and a low of -$4.3 million during Q4 2024
  • Its 5-year average for Non Operating Income is $200789.5, with a median of $118000.0 in 2022.
  • Its Non Operating Income has fluctuated over the past 5 years, first tumbled by 124423.08% in 2022, then skyrocketed by 110461.17% in 2025.
  • Over the past 5 years, Standard Biotools' Non Operating Income (Quarter) stood at -$52000.0 in 2021, then tumbled by 1244.23% to -$699000.0 in 2022, then soared by 257.22% to $1.1 million in 2023, then crashed by 491.9% to -$4.3 million in 2024, then surged by 51.43% to -$2.1 million in 2025.
  • Its last three reported values are -$2.1 million in Q3 2025, $5.0 million for Q2 2025, and $3.9 million during Q1 2025.